TrialFind
Saved trials

Filters

Status

Phase

Age group

TrialFind

Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

PrivacyData sourcesRegulatory infoContact
UnknownN/A

Data-Driven Characterization of Neuronal Markers During Deep Brain Stimulation for Patients With Parkinson's Disease

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has developed into a standard therapy in the refractory stage of Parkinson's disease (PD). Implanted micro- and macroelectrodes can be used to derive neural signals from the basa

Freiburg im Breisgau, Baden-Wurttemberg, GermanyView details
CompletedN/A

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF). Secondarily, the study monitors the results of subjective and objective findings as i

Rancho Mirage, California, United StatesView details
RecruitingN/A

Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients

Gait changes in Parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. The aim of this study is to collect gait measurements in Parkinson's patients through sensors in a novel shoe device, NUSHU

New York, New York, United StatesView details
TerminatedN/A

The Learning Effects of Attentional Strategy on Dual-task Walking in Patients With Parkinson's Disease: Behavioral Performance and Neural Plasticity

\[year1\] 1. To compare the effects of dual-task training with two different task priority instruction in people with Parkinson's disease and healthy controls on dual-task weight shifting performances.

Taipei, TaiwanView details
Recruiting

Italian Translation and Validation of the Non-Motor Fluctuation Assessment (NoMoFA) Questionnaire: an Observational, Multicentric, Cross-sectional, 6-months Duration Study on 200 Consecutive Parkinson's Disease Patients.

Parkinson's disease (PD) has been traditionally considered a movement disorder. In fact, it is now recognized as a multisystemic disease involving not only the central nervous system and presenting with a constellation of motor and non-moto

Torino, TO, ItalyView details
Completed

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms \[conditions that are PD look

Hershey, Pennsylvania, United StatesView details
Completed

The Benefits of Nature for Mood and Cognition in Persons With and Without Parkinson's Disease

This online study aims to explore the benefits of nature for mood and cognition in persons with and without Parkinson's disease. For the purpose of this survey, "natural environment" refers to places that primarily consist of natural elemen

Boston, Massachusetts, United StatesView details
UnknownPhase 2

Speech-in-Noise Treatments for Hypophonia in Parkinson's Disease

Hypophonia, or reduced speech intensity, is the most prevalent speech symptom in Parkinson's disease (PD) and often leads to significant difficulty communicating in most social situations. Behavioural treatments for hypophonia can be tempor

London, Ontario, CanadaView details
TerminatedN/A

Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease

Spinal cord stimulation (SCS) for Parkinson´s disease (PD) has been studied for a decade but consensus on efficacy is still lacking, with the previous stimulation standard paresthesia inducing threshold hampering adequate subject blinding.

São Paulo, São Paulo, BrazilView details
CompletedPhase 1

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).

Portland, Oregon, United StatesView details
CompletedPhase 2 / Phase 3

Treating Bacterial Overgrowth in Parkinson's Disease

This study investigates the effect of treating Small Intestinal Bacterial Overgrowth (SIBO) in patients with Parkinson's Disease (PD). It will test the hypothesis that treating SIBO with the antibiotic rifaximin will improve motor complicat

Cincinnati, Ohio, United StatesView details
Not yet recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.

Boston, Massachusetts, United StatesView details
CompletedPhase 2

Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients

The purpose of this study is to evaluate whether the DopaFuse System can reduce the fluctuation of plasma levodopa levels compared to participants' standard intermittent doses of oral LD/CD tablets (background treatment). It will also asses

Cassino, Italy+4 moreView details
TerminatedPhase 2 / Phase 3

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary effi

Phoenix, Arizona, United States+40 moreView details
CompletedPhase 4

OpiCapone Effect on Motor Fluctuations and pAiN

The aim of this study is to investigate the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with end-of-dose mot

London, United KingdomView details
Unknown

Rasagiline for Gait Treatment

Gait disturbances are very common and are a major cause for losing of independency in patients with advanced Parkinson's Disease (PD). The medical treatment of gait disturbances in advanced PD is very difficult and in many cases the classic

Multiple locationsView details
CompletedN/A

Photobiomodulation and Parkinson

This study aimed to assess the effects of transcranial photobiomodulation in patients with Parkinson's disease (PD).

León, Castille and León, Spain+1 moreView details
Unknown

Deep Brain Stimulation Therapy and Intestinal Microbiota

This study aims to observe the changes of intestinal microbiota after deep brain stimulation (DBS) therapy for Parkinson's disease, and explore the role of intestinal microbiota in the neuroprotective effect of DBS.

Nanjing, Jiangsu, ChinaView details
CompletedN/A

The Impact of Three Distinct Exercise Types on Fatigue, Anxiety, and Depression in Parkinson's Disease

The purpose of the study is to learn about the impact of exercise on fatigue, anxiety, and depression in Parkinson's disease. It is well established that exercise improves the motor symptoms of Parkinson's disease.

Lebanon, New Hampshire, United States+1 moreView details
Unknown

Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease

The project intends to assess the polygenic burden of rare disruptive mutations in Parkinson's disease (PD) and how they influence the phenotype/pathological heterogeneity of disease.

Pozzilli, ItalyView details
Load more trials